Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Retinoblastoma may occur with symptoms including white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

The retinoblastoma pipeline drugs market research report provides an analysis of the retinoblastoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases covering the product development milestones. Additionally, the report provides an overview of key players involved in therapeutic development for retinoblastoma and features dormant and discontinued projects.

Retinoblastoma Pipeline Drugs Market Segmentation by Targets

Some of the targets of the retinoblastoma pipeline drugs market are E3 Ubiquitin Protein Ligase Mdm2, Cells Expressing Anthrax Toxin Receptor 1, Cells Expressing Ganglioside GD2, Cellular Tumor Antigen p53, and DNA Topoisomerase I among others.

Retinoblastoma Pipeline Drugs Market Analysis, by Key Targets

Retinoblastoma Pipeline Drugs Market Analysis, by Key Targets

For more insights on key targets, download a free report sample

Retinoblastoma Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action of the retinoblastoma pipeline drugs market are E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, Cellular Tumor Antigen p53 Activator, Cytotoxic To Cells Expressing Anthrax Toxin Receptor 1, Cytotoxic To Cells Expressing Ganglioside GD2 and DNA Topoisomerase I Inhibitor among others.

Retinoblastoma Pipeline Drugs Market Analysis, by Key Mechanisms of Action

Retinoblastoma Pipeline Drugs Market Analysis, by Key Mechanisms of Action

For more insights on key mechanisms of action, download a free report sample

Retinoblastoma Pipeline Drugs Market Segmentation by Routes of Administration

The routes of administration in the retinoblastoma pipeline drugs market are intravenous, intravitreal, oral, intratumor, and ophthalmic.

Retinoblastoma Pipeline Drugs Market Analysis, by Routes of Administration

Retinoblastoma Pipeline Drugs Market Analysis, by Routes of Administration

For more insights on routes of administration, download a free report sample

Retinoblastoma Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the retinoblastoma pipeline drugs market are small molecule, fusion protein, oncolytic virus, subunit vaccine, and synthetic peptide.

Retinoblastoma Pipeline Drugs Market Analysis, by Molecule Types

Retinoblastoma Pipeline Drugs Market Analysis, by Molecule Types

For more insights on molecule type, download a free report sample

Competitive Landscape

Some of the key companies in the retinoblastoma pipeline drugs market are Aileron Therapeutics Inc, APEIRON Biologics AG, Ascentage Pharma Group International, Canget BioTekpharma LLC, Chengdu Kanghong Pharmaceuticals Group Co Ltd, and Cothera Bioscience Pty Ltd among others.

Retinoblastoma Pipeline Drugs Market Report Overview

Key Targets E3 Ubiquitin Protein Ligase Mdm2, Cells Expressing Anthrax Toxin Receptor 1, Cells Expressing Ganglioside GD2, Cellular Tumor Antigen p53, and DNA Topoisomerase I
Key Mechanisms of Action E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, Cellular Tumor Antigen p53 Activator, Cytotoxic To Cells Expressing Anthrax Toxin Receptor 1, Cytotoxic To Cells Expressing Ganglioside GD2, DNA Topoisomerase I Inhibitor
Key Routes of Administration Intravenous, Intravitreal, Oral, Intratumor, and Ophthalmic
Key Molecule Types Small Molecule, Fusion Protein, Oncolytic Virus, Subunit Vaccine, and Synthetic Peptide
Leading Companies Aileron Therapeutics Inc, APEIRON Biologics AG, Ascentage Pharma Group International, Canget BioTekpharma LLC, Chengdu Kanghong Pharmaceuticals Group Co Ltd, Cothera Bioscience Pty Ltd

Scope 

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Aileron Therapeutics Inc
APEIRON Biologics AG
Ascentage Pharma Group International
Canget BioTekpharma LLC
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cothera Bioscience Pty Ltd
Innovation Pharmaceuticals Inc
Oxular Ltd
PepVax Inc
Seneca Therapeutics Inc
Spectocular LLC
Targeted Therapy Technologies LLC
VCN Biosciences SL

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinoblastoma – Overview

Retinoblastoma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Retinoblastoma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoblastoma – Companies Involved in Therapeutics Development

Aileron Therapeutics Inc

APEIRON Biologics AG

Ascentage Pharma Group International

Canget BioTekpharma LLC

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Cothera Bioscience Pty Ltd

Innovation Pharmaceuticals Inc

Oxular Ltd

PepVax Inc

Seneca Therapeutics Inc

Spectocular LLC

Targeted Therapy Technologies LLC

VCN Biosciences SL

Retinoblastoma – Drug Profiles

APG-115 – Drug Profile

Product Description

Mechanism Of Action

History of Events

conbercept – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drug to Inhibit MDM2 for Retinoblastoma – Drug Profile

Product Description

Mechanism Of Action

History of Events

FL-761 – Drug Profile

Product Description

Mechanism Of Action

FL-7729 – Drug Profile

Product Description

Mechanism Of Action

FL-7N1 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Kevetrin – Drug Profile

Product Description

Mechanism Of Action

History of Events

lorukafusp alfa – Drug Profile

Product Description

Mechanism Of Action

History of Events

OXU-003 SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

PC-002p – Drug Profile

Product Description

Mechanism Of Action

PVX-301 – Drug Profile

Product Description

Mechanism Of Action

History of Events

sulanemadlin – Drug Profile

Product Description

Mechanism Of Action

History of Events

SVV-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

topotecan – Drug Profile

Product Description

Mechanism Of Action

History of Events

VCN-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Retinoblastoma – Dormant Projects

Retinoblastoma – Product Development Milestones

Featured News & Press Releases

Feb 08, 2022: Synthetic Biologics announces VCN Biosciences’ VCN-01 receives orphan drug designation for retinoblastoma from the U.S. FDA

Oct 12, 2020: Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for retinoblastoma treatment

Jan 24, 2019: SJD Barcelona Children’s Hospital is, for the first time in the world, treating a childhood cancer of the retina with the oncolytic virus VCN-01

Feb 29, 2016: VCN Biosciences Provides Update on its lead candidate VCN-01

Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma

Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma

Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma

Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma

Oct 31, 2012: VCN Biosciences at the 2012 Annual Meeting of the European Society of Cell & Gene Therapy in Versailles

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Retinoblastoma, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Retinoblastoma – Pipeline by Aileron Therapeutics Inc, 2022

Retinoblastoma – Pipeline by APEIRON Biologics AG, 2022

Retinoblastoma – Pipeline by Ascentage Pharma Group International, 2022

Retinoblastoma – Pipeline by Canget BioTekpharma LLC, 2022

Retinoblastoma – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2022

Retinoblastoma – Pipeline by Cothera Bioscience Pty Ltd, 2022

Retinoblastoma – Pipeline by Innovation Pharmaceuticals Inc, 2022

Retinoblastoma – Pipeline by Oxular Ltd, 2022

Retinoblastoma – Pipeline by PepVax Inc, 2022

Retinoblastoma – Pipeline by Seneca Therapeutics Inc, 2022

Retinoblastoma – Pipeline by Spectocular LLC, 2022

Retinoblastoma – Pipeline by Targeted Therapy Technologies LLC, 2022

Retinoblastoma – Pipeline by VCN Biosciences SL, 2022

Retinoblastoma – Dormant Projects, 2022

Figures

List of Figures

Number of Products under Development for Retinoblastoma, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, September 2026
$2,950 | October 2026
Pharmaceuticals
New
IDWeek 2026: Pre-Conference Coverage
$1,500 | October 2026
Pharmaceuticals
New
Gonorrhea: Market View, Current and Future Competitive Landscape
$3,495 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.